







Propanc




Everybody knows what cancer is

Cells in the body that start to divide rapidly and uncontrollably, with an ability to migrate from one location and spread to distant sites.

- Cancer cell
- Normal cell
- Blood cell




There are many factors which increase your risk of getting cancer.



But why does a cell become cancerous?










Because a cell becomes undifferentiated. In other words, the cell forgets how to do its job and invests all its energy in proliferating. Unlike normal cells, cancer cells multiply, but do not differentiate.




We all know someone who has suffered from this disease


How do common cancer therapies work?

These therapies take advantage of the uncontrolled proliferation of the cancer cells and kill these cells by targeting the cell division machinery. These therapies are effective but affect healthy cells as well, particularly those with a high rate of cell turnover, inducing undesirable side effects.

- | | |
|--|--|
|  1 Lung, liver, or kidney problems |  |
|  2 Fertility issues |  6 Dental problems |
|  3 Thyroid problems |  7 Hearing loss |
|  4 Heart problems |  8 Loss of hair |
|  5 Vision problems | |




What if the best way to stop cancer is not targeting tumor cell death, but inducing cell differentiation?



This is known as **differentiation therapy**. The key question here is to convince the malignant cells to stop proliferating and return to do their work as a specific cell type.

Advantages of differentiation therapy over conventional therapeutic strategies



Differentiation therapy does not target cell death, so healthy cells within the patient will not be compromised as it happens with chemotherapeutic drugs or gamma irradiation.

Differentiation therapy induces the cancer cells into the pathway of terminal differentiation and eventual senescence.

Differentiation therapy acts not only against cancer cells but interestingly can turn cancer stem cells (undifferentiated cells) towards completely differentiated (i.e. normal) cells.

What lesson can we learn from our own body?

Are there any natural elements within our organism that could help us fight against cancer?

As a matter of fact, yes there are: the enzymes, which are natural proteins that stimulate and accelerate biological reactions in the body. Particularly, the enzymes secreted by the exocrine pancreas that are essential for the digestion of proteins and fats.



Pancreatic Enzyme Therapy: An old story with promising implications

More than one hundred years ago, Professor John Beard first proposed that the pancreatic enzymes represent the body's primary defence against cancer and would be useful as a cancer treatment.

Since then, several scientists have endorsed Beard's hypothesis with encouraging data from patient treatment.

PANCREATIC SECRETION

- Trypsinogen
- Chymotrypsinogen
- Pancreatic lipase and amylase



What are we offering?

PROPANC is developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumour recurrence and metastasis, the main cause of patient death from cancer.

Our lead product, **PRP**, is a novel, patented, formulation consisting of two proenzymes mixed in a synergetic ratio.

What we have achieved

After extensive laboratory research and a limited amount of human testing, we have evidence that **PRP**:


- Reduces cancer cell growth via promotion of cell differentiation;
- Enhances cell adhesion and may suppress metastasis progression;
- Has no serious side effects and improves patient survival.



Pancreatic pro-enzyme therapy: Mechanism of action

Why does metastasis occur?

Because a program inside the cell called the Epithelial-Mesenchymal Transition (EMT) is activated, which causes epithelial cancer cells to become invasive and stem cell-like, features which then allow these cancer cells to spread and metastasize.



The Company

Who we are

Our thinking

Our new cancer treatment is based on the original work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago, using fresh pancreatic enzyme extracts.

Through advancements in science and technology, our company has discovered an opportunity to commercialize an improved version of this treatment. Our intention is to supply this treatment to markets worldwide.

Propanc was established in 2007 and is located in Melbourne, Australia. The Company anticipates establishing global markets for its technologies.



Propanc

Highlights

Key features

Global demand for effective, safe and easy to administer cancer treatments is increasing rapidly;

Propanc seeks worldwide regulatory approval in several therapeutic indications targeting tumor types where a medical need is established and few treatment options exist;

Propanc is building an IP portfolio around its scientific understanding of the effects of proenzymes in cancer, identifying new formulations, new routes of administration and potential new therapeutic targets.

Market opportunity:

Growing demand for new cancer treatments as a result of a rapidly ageing population and changing environmental factors in western countries. According to the World Health Organization, all cancers (excluding non-melanoma skin cancer) are expected to increase from 8.2 million annual deaths in 2012 to over 10 million annual deaths by 2020, exceeding 13 million annual deaths by 2030.





Propanc

For more information contact:

James Nathanielsz B.App.Sc, MEI
Chief Executive Officer

Level 2, 555 Riversdale Road
Camberwell, VIC 3124 AUSTRALIA
Ph: +61 (0) 3 9882 0780
Cell: +61 (0) 414 835 002
Fax: +61 (0) 3 9882 9969

Website: www.propanc.com

The information is based on published researchn:

"In vitro treatment of carcinoma cell lines with pancreatic (pro)enzymes suppresses the EMT programme and promotes cell differentiation".

Perán M, Marchal JA, García MA, Kenyon J, Tosh D.
Cellular Oncology. 2013 Jul; 36(4): 289–301.

The text has been adapted by Dr. M Perán.

Illustrations by Tomás Justicia

CONFIDENTIAL INFORMATION. This information is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy any security or related financial instrument. The summary may include "forward-looking statements" with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934 and are intended to be covered by the safe harbor provisions for forward looking statements. This information is supplied from sources we believe to be reliable but we cannot guarantee accuracy. This document and the information contained herein is confidential. This document has been furnished to you solely for your information. The information contained herein may not be reproduced, disclosed or redistributed, in whole or in part, by mail, facsimile, electronic or computer transmission or by any other means to any other person, except with prior written consent of the Company. The material has been prepared or is distributed solely for information purposes and is not a solicitation or an offer to buy any security or instrument or to participate in any trading strategy.